Depression severity

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

ERT produced statistically and clinically significant reductions in depression severity compared to modified attention control, with large effect sizes on MDD CSR and BDI-II, and 63% of the comorbid M

Effect: improvement; Hedge's g = .82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82

Androgen deprivation therapy in men with prostate cancer was associated with statistically significant worsening of depression scores on the PHQ-9 over 6 months compared to eugonadal controls.

Effect: adverse; 0.93; CI: 95%CI= 0.04 to 1.82